9

1

ABSTRACT

Epidemiology of Coccidian Parasites in HIV

Patients of Northern Uganda

Original Research Article

Aim: The epidemiology of coccidian parasites in HIV patients of sub Saharan Uganda is poorly understood. The aim of the study was to determine the epidemiology of coccidian parasites and their associated risk factors. This was a cross sectional study carried out in Arua district in West Nile region of Northern Uganda for a period of five months.

Materials and methods: Participants in the study included HIV positive patients presenting with diarrhea. A total of 111 patients were included and classified into children, adults and elderly. A structured questionnaire was administered and stool samples were obtained using sterile stool containers and laboratory analysis was carried out using modified ZN technique. Ethical clearance was acquired and the consent of the patients was sought.

Results and discussion: Coccidian prevalence of 5.4% in HIV patients was shown and the most prevalent coccidian species that were identified included *Cryptosporidium parvum* (3.6%) and *Isospora belli* (1.8%) and these were most prevalent in females (5.7%). The major risk factors associated were shown to be mainly consumption of water from tap and bore hole. Community lifestyle patterns are major contributing factors to the epidemiology of the condition. HIV patients on septrin® and drinking boiled water were shown to have a low prevalence of coccidian parasites i.e. 1.9% and 2.6% respectively probably due to the increased immunity compared to HIV patients not on therapy. Patients taking septrin® and boiling water were shown to be associated (P < 0.05) with low infections.

Conclusion and recommendations: The study further highlighted the importance to control secondary infections in HIV patients regardless of age and social status especially in HIV patients living in rural communities.

10

11 Keywords: "Coccidia in Humans," "Coccidia in HIV patients," "Coccidia risk factors,"
12 "Cryptosporidium in Uganda," "Diarrhea in HIV patients."
13

14 **1. INTRODUCTION**

15

16 Coccidian parasitic infections have altered the epidemiology and outcome of Human 17 immunodeficiency virus (HIV) patients in sub-Saharan Africa [1]. Diarrhea has been 18 identified as a major presenting complaints in HIV-infected patients. Because of the delayed 19 diagnosis of these pathogens in HIV infected patients, the patients usually take medication 20 without prescription from clinicians as well as local medications for treatment of signs and symptoms, therefore the disease is not treated especially in sub Saharan Uganda due to the 21 22 liberalization of the medical drug industry and poorly regulated herbal therapies [1] [2] [3]. The epidemiology of coccidian parasites in HIV patients of sub Saharan origin is poorly 23 understood. In a recent study in Ethiopia, prevalence of gastro intestinal parasites was 24 25 shown to range between 18% - 40%. Infection with Cryptosporidium spp was found to be 26 associated with lowered immunity and the major risk factors were absence of toilets, water 27 source and poor standards of living [4]. In a previous study in Ethiopia the prevalence of Cryptosporidium parvum (C. parvum) and Isospora belli (I. belli) were shown to be 20.8% 28 29 and 7.9% respectively in HIV patients [5].

30 A recent study in Kenya has shown a prevalence of 50.9% of enteric parasites which were 31 waterborne. The major risk factors identified in the study were; place of residence, agro-32 ecological, water source, family size, location, reliability, treatment and diarrheal status 33 probably due to poor environmental sanitation and personal hygiene, food and individual 34 contamination probably due to poor management and care of HIV patients [6]. 35 Contamination of water with coccidian spp has been reported national water storage facilities 36 [7]. Infection rates are highest in children living in sub-Saharan Africa and clinical cases are 37 expected to be higher than reported due to limited infrastructure and research in the region 38 [8] [9]. The current control strategies are towards community drug delivery of anti-helminthic 39 drugs against intestinal parasites but there is none against coccidian parasites [3]. 40 Stimulating research and development in rural communities through support of clinical trials 41 to improve treatment, in addition to securing and increasing drug availability, needs 42 governmental funding and resources that do not presently exist in most sub Saharan health 43 care facilities [9].

44 Coccidian parasites are well recognized and account for about 20% of diarrheal episodes in 45 children in developing countries and up to 9% of episodes in developed settings and causes 46 a considerable amount of diarrheal illness in young farm animals worldwide [2]. Sporadic 47 outbreaks among children in developed countries have been reported due to fecal-oral 48 transmission [1]. Epidemiological variations have been observed in the socioeconomic and 49 geographical effects of the distribution of coccidian parasites in humans that may influence 50 the sources and routes of transmission. The study was carried out to highlight the 51 importance of screening for intestinal coccidian parasites among HIV patients and also to 52 emphasize the necessity of increasing awareness among clinicians regarding the 53 occurrence and management of these parasites in the region.

54

55

56 2. MATERIAL AND METHODS

57

58 This was a cross sectional study carried out in Arua regional referral hospital in West Nile 59 region of Northern Uganda for a period of five months (January to May 2013). Participants in 60 the study included HIV positive patients presenting with diarrhea and excluded those without 61 diarrhea. A total of 111 patients was used and classified into children (10-19 years), adults 62 (20-39 years) and elderly (40-69 years). A structured guestionnaire was administered and 63 stool samples were obtained using sterile stool containers and laboratory analysis was 64 carried out to identify the parasites using formal ether concentration technique and modified 65 ZN. Briefly; 10 ml of 10% formol-saline was added to 2g of faeces in a centrifuge tube and stirred using an applicator stick filtered into a centrifuge tube. 3 ml of ether was added, 66 mixed well centrifuged at 3,000 rpm for 5 minutes. The sediment was then re-suspended by 67 68 tapping the bottom of the tube. Mixed well and transferred to a slide for microscopic 69 examination under a cover slip and viewed under microscope x10 objective and the findings 70 were recorded. A small portion of the stool sediment that was concentrated was taken and a 71 smear made on a clean slide. The smear was allowed to air dry then fixed with absolute 72 methanol. The smear was stained with strong carbol fuchsin for 30 minutes, decolorised with 73 1% acid alcohol and rinsed with water and counter stained with 0.1% methylene blue. The 74 slides were viewed under x100 objective. Data was recorded as frequency and expressed as 75 percentages. Descriptive analysis using SPSS version 20 was carried out to determine 76 associations and a p-value < 0.05 was considered statistically significant.

77

78 79

3. RESULTS AND DISCUSSION 80

The study showed a Coccidian prevalence of 5.4% in HIV patients as shown in Table 1. 82

83 84

81

Table 1 Showing prevalence of Coccidian parasites in HIV patients.

85

Parameter Frequency (%) Negative positive 105 (94.6) **HIV** patients 6 (5.4)

86

The most prevalent coccidian species that were identified in HIV patients included C. parvum 87 88 (3.6%) and *I. belli* (1.8%) as shown in **Table 2**.

89 90 91

Table 2 Showing Coccidian species prevalent in HIV patients

Species	Frequency (%)	
C. parvum	(3.6)	
I. belli	2 (1.8)	

92

93 The distribution of the parasites was shown to be 5.7% in females and 4.9% in males. The 94 risk factors associated with coccidian parasites in the study area were shown to be mainly 95 from tap 12.9% and bore hole 2.7% as shown in Table 3.

96

97 Table 3 Showing descriptive statistics from the questionnaire

98

		Positive	Negative
Parameter	Variables		
		Frequency (%)	
Gender	Female	4 (5.7)	66 (94.3)
	Male	2 (4.9)	39 (95.1)
Age	Children	14 (100)	0 (0)
	Adults	4 (6.3)	59 (93.7)
	Elderly	2 (5.9)	32 (94.1)
Risk factors	Bore hole	2 (2.7)	72 (97.3)
	Тар	4 (12.9)	27 (87.1)
	River	0 (0)	2 (100)
	Community well	0 (0)	4 (100)
Water quality	Drink boiled water	1 (2.6)	38 (97.4)
	Drink raw water	5 (6.9)	67 (93.1)
Prophylaxis treatment	Taking septrin®	1 (1.9)	51 (98.1)
	Not taking septrin®	5 (8.5)	54 (91.5)

99

100 HIV patients on septrin® and drinking boiled water were shown to have a low prevalence of

101 coccidian parasites i.e. 1.9% and 2.6% respectively. Further analysis showed

102

103

The study showed a prevalence of 5.4% which is steadily increasing especially in HIV children and the most prevalent coccidian species was identified as *C. parvum* with most cases being in children as shown in **Table 1** and **Table 2**. A study in central Uganda revealed a prevalence of 25% in a population of over 1000 children suffering from diarrhea due to *C. Parvum* [10].

109 The major risk factor associated with coccidian parasites in the study was consumption of 110 raw drinking water from the bore hole and the taps (Table 3). Community lifestyle patterns 111 such as poor hygiene, poor nutrition standards and challenges associated with preparation 112 of safe drinking water such as scarcity of fuel (fire wood) and transport to collect fire wood 113 from distant woods are responsible for the laziness amongst community members to prepare 114 safe drinking water which is in agreement with a recent study [3]. Poor sanitation habits such 115 as failure to clean water collecting jerricans over long periods of time is a major factor 116 observed leading to contamination of water collected from bore holes in the communities [4]. 117 Due to challenges of financing which is characteristic of sub-Saharan African local 118 government, serving of water pipes is hardily carried out thus leading to sporadic leakages 119 and contamination of the water [9]. This has subsequently led to increased episodes of 120 infections in rural communities that are often forced to share the limited water sources 121 especially in the dry seasons.

122 Patients actively on septrin® treatment were found to have a low prevalence probably due to 123 the increased immunity compared to HIV patients not on therapy as shown in Table 3. 124 Children are associated with a weak immunity and coupled with poor nutritional habits they 125 are highly predisposed to secondary infections than adults [11] [12] [13]. Inferential analysis 126 showed there existed a stronger relationship in drinking boiled water and septrin[®]. This 127 would be due to the added advantage of boiled water where by the eggs and parasites are 128 killed thus breaking the lifecycle. Patients on septrin® are sub clinically infected as they 129 appear to have improved immunity against the parasites. Major constraints to the study 130 included; small sample size and limited number of diagnostic tools used due to severe 131 financial constraints.

132

133

134 4. CONCLUSION

135

The prevalence of coccidian parasites in HIV patients was shown to be >5% and the major risk factors identified were consumption of un-boiled water from the taps and bore holes. HIV patients on prophylactic treatment were shown to have an added advantage than those who were not. The study further highlighted the importance to control secondary infection in HIV patients regardless of age and social status.

Patients with HIV living in rural communities where it is difficult to access safe drinking water should be encouraged to take prophylactic treatments seriously. A further study should be conducted in the region using a wider array of diagnostic tools to determine the scale of diarrheal diseases in HIV patients.

145 146

147 CONSENT

148

149 I am a research student working on a research project to determine the prevalence of 150 Intestinal coccidian parasites among HIV patients presenting with diarrhea. If you change 151 your mind about participating during the course of the study, you have the right to withdraw at any time. If there is anything that is not clear or you need further information, we shall be
delighted to provide it.

155 **Declaration of the patient**

.....

156 I have understood the purpose of the study, I realize that I may be contacted again if need 157 be. I have read the information or it has been read to me. I have had the opportunity to ask questions about it and any questions that I have asked have been answered to my 159 satisfaction. I consent voluntarily to participate as a subject in this study and I have the right 160 to withdraw from the study at any time without any way affecting my health.

NAME/ SIGNATURE OF VOLUNTEER/ PATIENT

NAME/ SIGNATURE OF INVESTIGATOR

.....

164 165 166

162

163

167 ETHICAL APPROVAL

168 A copy of this research report was submitted to the Department of Medical Laboratory 169 Sciences and MUST Research Ethical Committee for approval. Permission was sought from 170 the hospital director, laboratory in-charge and head of HIV clinic Arua R.R Hospital. The 171 purpose of this study including the procedure of specimen collection was explained to the 172 participants. Consent of the patients was sought prior to recruitment for the study and the 173 consent form was filled and signed by the patients. The consent form was translated into the 174 local language and all participants/patients understood all the details of the study. Laboratory results of the patients were given to the clinicians concerned and all patients/participants 175 176 were guided on how to get their results or any help from the hospital.

177 178

179 **REFERENCES**

180

181 [1]. Agholi, M., Hatam, G. R., & Motazedian, M. H. (2012). HIV/AIDS-Associated
182 Opportunistic Protozoal Diarrhea. *AIDS Research and Human Retroviruses*, *29*(1),
120911064948006. doi:10.1089/AID.2012.0119

184 [2]. Cook, G. C. (1991). Tropical medicine. *Postgrad Med J*, *67*, 798–822.

185 [3]. Fletcher, S. M., Stark, D., Harkness, J., & Ellis, J. (2012). Enteric protozoa in the 186 developed world: A public health perspective. *Clinical Microbiology Reviews*, *25*(3), 420– 187 449. doi:10.1128/CMR.05038-11

[4]. Missaye, A., Dagnew, M., Alemu, A., & Alemu, A. (2013). Prevalence of intestinal parasites and associated risk factors among HIV/AIDS patients with pre-ART and on-ART attending dessie hospital ART clinic, Northeast Ethiopia. *AIDS Research and Therapy*, *10*(1), 7. doi:10.1186/1742-6405-10-7

[5]. Endeshaw, T., Mohammed, H., & Woldemichael, T. (2004). Cryptosporidium parvum and
other instestinal parasites among diarrhoeal patients referred to EHNRI in Ethiopia. *Ethiopian Medical Journal*, 42(3), 195–8. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/16895037

- 196 [6]. Kipyegen, C. K., Shivairo, R. S., & Odhiambo, R. O. (2012). Prevalence of intestinal 197 parasites among HIV patients in Baringo, Kenya. *The Pan African Medical Journal*, *13*, 37.
- 198 [7]. Puleston, R. L., Mallaghan, C. M., Modha, D. E., Hunter, P. R., Nguyen-Van-Tam, J. S.,
- Regan, C. M., ... Chalmers, R. M. (2014). The first recorded outbreak of cryptosporidiosis
 due to Cryptosporidium cuniculus (formerly rabbit genotype), following a water quality
 incident. *Journal of Water and Health*, *12*(1), 41–50. doi:10.2166/wh.2013.097
- [8]. Raccurt, C. P., Fouché, B., Agnamey, P., Menotti, J., Chouaki, T., Totet, A., & Pape, J.
 W. (2008). Short report: Presence of Enterocytozoon bieneusi associated with intestinal

204 coccidia in patients with chronic diarrhea visiting an HIV center in Haiti. *American Journal of* 205 *Tropical Medicine and Hygiene*, *79*(4), 579–580.

206 [9]. Michael, H. O., Horton, J., & Piero, O. L. (2010). Epidemiology and control of human 207 gastrointestinal parasites in children. *Expert Rev Anti Infect Ther*, *8*(2), 219–234. 208 doi:10.1586/eri.09.119.Epidemiology

[10]. Tumwine, J. K., Kekitiinwa, A., Nabukeera, N., Akiyoshi, D. E., Rich, S. M., Widmer, G.,
... Tzipori, S. (2003). Cryptosporidium parvum in children with diarrhea in Mulago Hospital,
Kampala, Uganda. *The American Journal of Tropical Medicine and Hygiene*, *68*(6), 710–5.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12887032

[11]. Schürmann, D., Bergmann, F., Albrecht, H., Padberg, J., Wünsche, T., Grünewald, T.,
... Suttorp, N. (2002). Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary
prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with
advanced HIV infection. *European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 21*(5), 353–61.
doi:10.1007/s10096-002-0723-3

[12]. Rogerson, S. R., Gladstone, M., Callaghan, M., Erhart, L., Rogerson, S. J., Borgstein,
E., & Broadhead, R. L. (2004). HIV infection among paediatric in-patients in Blantyre,
Malawi. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, *98*(9), 544–
552.

[13]. Behera, B., Mirdha, B. R., Makharia, G. K., Bhatnagar, S., Dattagupta, S., &
Samantaray, J. C. (2008). Parasites in patients with malabsorption syndrome: A clinical
study in children and adults. *Digestive Diseases and Sciences*, *53*(3), 672–679.

227 APPENDIX

Microscopic identification of the parasites

Cryptosporidium Parvum

Echoru. I et al., 2015



QUESTIONNAIRE

Now that you have accepted to be part of this study, may you avail the following information about yourself? 275 276 Patient's identification code: 277 Date: 278 279 280 Sex: A. Female B. Male (tick one) 281 Age (years): 1. Do you know your HIV status? And if yes what is it? 282 283 A. Positive B. Negative 284 2. Do you have diarrhea? And if yes, how long have you had it? 285 286 3. Do you take septrin® as prophylaxis treatment? 287 A. Yes B. No 288 4. Where do you get you water for domestic use? A. Community well C. Bore hole 289 291 B. Tap D. Others specify 290 292 5. Do you boil drinking water at home? 293 A. Always 294 296 C. Not at all B. Some times 295 297 6. If you do not boil drinking water, can you briefly explain why? 298 299 7. Do you clean the jerricans that you use for collecting water? 300 A. Yes B. No 301 8. If yes, how often do you clean the jerricans? B. Weekly 302 A. Daily C. Monthly D. Annually E. Others specify..... 303 304 Client signature...... Researchers' signature..... 305